104 related articles for article (PubMed ID: 18976668)
21. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
22. Selection and growth regulation of genetically modified cells with hapten-specific antibody/receptor tyrosine kinase chimera.
Tanaka K; Kawahara M; Ueda H; Nagamune T
Biotechnol Prog; 2009; 25(4):1138-45. PubMed ID: 19569211
[TBL] [Abstract][Full Text] [Related]
23. Receptor tyrosine kinases regulate alpha1D-adrenoceptor signaling properties: phosphorylation and desensitization.
Rodríguez-Pérez CE; Calvo-Ochoa E; Kalashnikova EV; Reyes-Cruz G; Romero-Avila MT; García-Sáinz JA
Int J Biochem Cell Biol; 2009 Jun; 41(6):1276-83. PubMed ID: 19038360
[TBL] [Abstract][Full Text] [Related]
24. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.
Burke CL; Stern DF
Mol Cell Biol; 1998 Sep; 18(9):5371-9. PubMed ID: 9710621
[TBL] [Abstract][Full Text] [Related]
25. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
26. Effects of ceramide, ceramidase inhibition and expression of ceramide kinase on cytosolic phospholipase A2alpha; additional role of ceramide-1-phosphate in phosphorylation and Ca2+ signaling.
Shimizu M; Tada E; Makiyama T; Yasufuku K; Moriyama Y; Fujino H; Nakamura H; Murayama T
Cell Signal; 2009 Mar; 21(3):440-7. PubMed ID: 19101626
[TBL] [Abstract][Full Text] [Related]
27. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
Choudhary C; Olsen JV; Brandts C; Cox J; Reddy PN; Böhmer FD; Gerke V; Schmidt-Arras DE; Berdel WE; Müller-Tidow C; Mann M; Serve H
Mol Cell; 2009 Oct; 36(2):326-39. PubMed ID: 19854140
[TBL] [Abstract][Full Text] [Related]
28. Effect of diadenosine polyphosphates in achondroplasic chondrocytes: inhibitory effect of Ap4A on FGF9 induced MAPK cascade.
Guzmán-Aránguez A; Irazu M; Yayon A; Pintor J
Biochem Pharmacol; 2007 Aug; 74(3):448-56. PubMed ID: 17543287
[TBL] [Abstract][Full Text] [Related]
29. The A391E mutation enhances FGFR3 activation in the absence of ligand.
Chen F; Degnin C; Laederich M; Horton WA; Hristova K
Biochim Biophys Acta; 2011 Aug; 1808(8):2045-50. PubMed ID: 21536014
[TBL] [Abstract][Full Text] [Related]
30. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases.
Abella JV; Park M
Am J Physiol Endocrinol Metab; 2009 May; 296(5):E973-84. PubMed ID: 19240253
[TBL] [Abstract][Full Text] [Related]
31. FGFR3 unliganded dimer stabilization by the juxtamembrane domain.
Sarabipour S; Hristova K
J Mol Biol; 2015 Apr; 427(8):1705-14. PubMed ID: 25688803
[TBL] [Abstract][Full Text] [Related]
32. Studies of receptor tyrosine kinase transmembrane domain interactions: the EmEx-FRET method.
Merzlyakov M; Chen L; Hristova K
J Membr Biol; 2007 Feb; 215(2-3):93-103. PubMed ID: 17565424
[TBL] [Abstract][Full Text] [Related]
33. Specific inhibition of FGF-2 signaling with 2-O-sulfated octasaccharides of heparan sulfate.
Ashikari-Hada S; Habuchi H; Sugaya N; Kobayashi T; Kimata K
Glycobiology; 2009 Jun; 19(6):644-54. PubMed ID: 19254961
[TBL] [Abstract][Full Text] [Related]
34. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
35. Insulin increase in MAP kinase phosphorylation is shifted to early time-points by overexpressing APS, while Akt phosphorylation is not influenced.
Onnockx S; Xie J; Degraef C; Erneux C; Pirson I
Exp Cell Res; 2009 Sep; 315(15):2479-86. PubMed ID: 19527711
[TBL] [Abstract][Full Text] [Related]
36. Quantitative modeling perspectives on the ErbB system of cell regulatory processes.
Lazzara MJ; Lauffenburger DA
Exp Cell Res; 2009 Feb; 315(4):717-25. PubMed ID: 19022246
[TBL] [Abstract][Full Text] [Related]
37. Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains.
Escher C; Cymer F; Schneider D
J Mol Biol; 2009 May; 389(1):10-6. PubMed ID: 19361517
[TBL] [Abstract][Full Text] [Related]
38. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
Grunt TW; Wagner R; Grusch M; Berger W; Singer CF; Marian B; Zielinski CC; Lupu R
Biochem Biophys Res Commun; 2009 Jul; 385(3):454-9. PubMed ID: 19467222
[TBL] [Abstract][Full Text] [Related]
39. Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.
Chen F; Sarabipour S; Hristova K
PLoS One; 2013; 8(2):e56521. PubMed ID: 23437153
[TBL] [Abstract][Full Text] [Related]
40. Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics.
Minor LK
Expert Rev Mol Diagn; 2005 Jul; 5(4):561-71. PubMed ID: 16013974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
